Literature DB >> 27932228

The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma.

Jean-Charles Nault1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27932228     DOI： 10.1016/S0140-6736(16)32480-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Transcriptomics Associates Molecular Features with 18F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma.

Authors:  Sandi A Kwee; Maarit Tiirikainen; Miles M Sato; Jared D Acoba; Runmin Wei; Wei Jia; Loic Le Marchand; Linda L Wong
Journal:  Cancer Res       Date:  2019-02-13       Impact factor: 12.701

2.  Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.

Authors:  Sang Min Yoon; Baek-Yeol Ryoo; So Jung Lee; Jong Hoon Kim; Ji Hoon Shin; Ji Hyun An; Han Chu Lee; Young-Suk Lim
Journal:  JAMA Oncol       Date:  2018-05-01       Impact factor: 31.777

Review 3.  Systemic Treatment for Advanced Hepatocellular Carcinoma.

Authors:  Mohamed Bouattour; Neil Mehta; Aiwu R He; Emil I Cohen; Jean-Charles Nault
Journal:  Liver Cancer       Date:  2019-03-06       Impact factor: 11.740

4.  Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.

Authors:  Linlin Liu; Xiaoyang Sun; Yu Xie; Yinping Zhuang; Ruosi Yao; Kai Xu
Journal:  Biosci Rep       Date:  2018-07-12       Impact factor: 3.840

5.  Role of local treatment including radiotherapy in Barcelona Clinic of Liver Cancer stage C patients: a nationwide cohort analysis in South Korea.

Authors:  Jeongshim Lee; Won Sup Yoon; Woong Sub Koom; Chai Hong Rim
Journal:  Cancer Manag Res       Date:  2019-02-11       Impact factor: 3.989

6.  Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR-422a/PDK2 axis.

Authors:  Feifei Wei; Liang Yang; Dandan Jiang; Min Pan; Guiyan Tang; Mingyue Huang; Jing Zhang
Journal:  Cancer Med       Date:  2020-02-05       Impact factor: 4.452

7.  MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway.

Authors:  Ying Yang; Zhifang Yang; Ruili Zhang; Chunli Jia; Rui Mao; Shaya Mahati; Yuefen Zhang; Ge Wu; Yan Na Sun; Xiao Yan Jia; Ainiwaer Aimudula; Hua Zhang; Yongxing Bao
Journal:  Biosci Rep       Date:  2021-12-22       Impact factor: 3.840
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.